Last reviewed · How we verify
Regorafenib Pill
At a glance
| Generic name | Regorafenib Pill |
|---|---|
| Also known as | STIVARGA |
| Sponsor | Teclison Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TATE and Pembrolizumab (MK3475) in mCRC and NSCLC (PHASE2)
- Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Regorafenib Pill CI brief — competitive landscape report
- Regorafenib Pill updates RSS · CI watch RSS
- Teclison Ltd. portfolio CI